Palisade Bio PALI 深 沪
等待开盘 04-02 09:30:00 美东时间
1.88
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 1.88
- 总市值 3.12亿
- 52周最高 2.64
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.53
- 委 比 0.00%
- 总股本 1.66亿
- 历史最高 18405.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.53
- 每 手 1
- 风险率 0.59%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 大摩、高盛上调Denali Therapeutics目标价；Chewy、沛齐遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Atossa Therapeutics"买入"评级，目标价从7美元升至25美元；Needham：维持Nkarta"买入"评级，目标价从10美元升至11美元
03-27 10:22
HC Wainwright & Co. Initiates Coverage On Palisade Bio with Buy Rating, Announces Price Target of $7
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Palisade Bio (NASDAQ:PALI) with a Buy rating and announces Price Target of $7.
03-26 20:43
美股大行评级 | 大摩将应用材料目标价升至432美元；潜在涨幅200.0%！维尔生物科技获巴克莱升目标价至30美元，维持"超配"评级
今日重点评级关注：巴克莱：维持Vir Biotechnology"超配"评级，目标价从26美元升至30美元；巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从10美元升至11美元
02-26 09:30
Stifel Initiates Coverage On Palisade Bio with Buy Rating, Announces Price Target of $5
Stifel analyst Alex Thompson initiates coverage on Palisade Bio (NASDAQ:PALI) with a Buy rating and announces Price Target of $5.
02-25 18:47
Palisade Bio Appoints Bram Verstockt to Clinical Advisory Board
Palisade Bio Appoints Bram Verstockt to Clinical Advisory Board Palisade Bio Inc. has appointed Bram Verstockt, MD, PhD, an expert in inflammatory bowel disease and precision medicine, to its Clinical Advisory Board. This move supports the company's Phase 2 development plans for PALI-2108 in ulcerat
02-17 21:45
Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board
Palisade Bio appoints Bram Verstockt, MD, PhD, to its Clinical Advisory Board to strengthen Phase 2 development of PALI-2108 for ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD). Verstockt, an expert in IBD and precision medicine, will contribute his expertise in advanced imaging, biomarkers, and multi-omics research. Palisade plans to submit an IND for a Phase 2 UC study in early 2026. PALI-2108 is a targeted PDE4 inhibitor prodr...
02-17 13:45
Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium
Palisade Bio, Inc. announced that its CEO, JD Finley, and President and Chief Medical Officer, Dr. Mitchell Jones, will participate in a virtual fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium on February 12, 2026. The event will also feature one-on-one meetings between company management and investors. Palisade Bio is focusing on advancing PALI-2108, a once-daily oral PDE4 inhibitor prodrug designed for targeted ...
02-09 14:00
Palisade Bio präsentiert auf Oppenheimer Healthcare Life Sciences Conference
Palisade Bio präsentiert auf Oppenheimer Healthcare Life Sciences Conference Palisade Bio Inc. wird am Donnerstag, den 26. Februar 2026, von 12:40 bis 13:10 Uhr ET eine virtuelle Präsentation auf der Oppenheimer 36th Annual Healthcare Life Sciences Conference halten. Das Management steht zudem für E
02-05 21:45
Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board
Palisade Bio announced the appointment of IBD experts Laurent Peyrin-Biroulet, MD, PhD, and David T. Rubin, MD, to its Clinical Advisory Board. Their expertise includes ulcerative colitis, Crohn’s disease, and clinical trial design. Palisade Bio is advancing PALI-2108 toward Phase 2 development for ulcerative colitis and fibrostenotic Crohn’s disease. The drug is a once-daily oral PDE4 inhibitor prodrug targeting the terminal ileum and colon, aim...
01-29 13:45
Palisade Bio Two Abstracts Selected For Poster Presentation At Two Premier International Inflammatory Bowel Diseases Meetings
Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the
01-16 21:33
